Grace Therapeutics
GRCE
34 hedge funds and large institutions have $19.7M invested in Grace Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
48% more funds holding
Funds holding: 23 → 34 (+11)
32% more capital invested
Capital invested by funds: $15M → $19.7M (+$4.75M)
4% more call options, than puts
Call options by funds: $326K | Put options by funds: $314K
0.41% less ownership
Funds ownership: 27.97% → 27.56% (-0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$2.97M |
| 2 |
Cerity Partners
New York
|
+$1.67M |
| 3 |
Jane Street
New York
|
+$656K |
| 4 |
Renaissance Technologies
New York
|
+$448K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$359K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.15M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.22M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.77M |
| 4 |
Morgan Stanley
New York
|
-$82.1K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$48K |
GRCE Hedge Fund Activity: Q1 2026 in Review
34 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2026, worth a combined $19.7M — up 32% from $15M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GRCE positions and 5 closed out — a net gain of 13 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $2.97M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $3.15M sold.
- 34 institutional investors held Grace Therapeutics (GRCE) as of Q1 2026, up from 23 in Q4 2025.
- Funds reported $19.7M of Grace Therapeutics stock for Q1 2026, up 32% quarter-over-quarter.
- 18 funds opened new Grace Therapeutics positions in Q1 2026 and 5 closed out, a net change of +13 holders.
- The largest Grace Therapeutics buyer in Q1 2026 was Eversept Partners, an estimated $2.97M added.
- The largest Grace Therapeutics seller in Q1 2026 was AIGH Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q1 2026.